New data to be presented by Merck & Co. Inc. at the upcoming American Society of Clinical Oncology virtual meeting represent a step forward in its bid to challenge Roche’s stronghold in immunotherapy for triple-negative breast cancer. However, Roche need not start quaking in its boots just yet.
Merck is set to present updated results on its PD-1 inhibitor Keytruda (pembrolizumab) in first-line treatment of triple-negative breast cancer...








